Ken Griffin Glycomimetics Inc Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$0.24 - $3.04 $1,800 - $22,800	-7,500 Reduced 13.18%	49,400 $13,000
Q1 2024 May 15, 2024	BUY	$2.55 - $3.49 $130,304 - $178,339	51,100 Added 881.03%	56,900 $170,000
Q4 2023 Feb 14, 2024	BUY	$1.13 - $2.54 $6,553 - $14,732	5,800 New	5,800 $13,000
Q2 2023 Aug 14, 2023	SELL	$1.21 - $2.08 $174,119 - $299,312	-143,900 Reduced 89.99%	16,000 $27,000
Q1 2023 May 15, 2023	BUY	$1.25 - $4.05 $41,000 - $132,840	32,800 Added 25.81%	159,900 $201,000
Q4 2022 Feb 14, 2023	BUY	$0.57 - $3.03 $72,447 - $385,113	127,100 New	127,100 $385,000

17.7M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $13.1M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.